title: Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.
abstract: Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.
authors: Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, MA, USA. ychen6@partners.org
authors: Yi-Bin
authors: YB
authors: Chen
authors: Jessica P
authors: JP
authors: Driscoll
authors: Steven L
authors: SL
authors: McAfee
authors: Thomas R
authors: TR
authors: Spitzer
authors: Eric S
authors: ES
authors: Rosenberg
authors: Rebecca
authors: R
authors: Sanders
authors: Ronald B
authors: RB
authors: Moss
authors: Fang
authors: F
authors: Fang
authors: Francisco M
authors: FM
authors: Marty
mesh_terms: D000280:Administration, Inhalation; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008875:Middle Aged; D009305:Nasopharynx / Q000821:virology; D010100:Oxygen / Q000097:blood; D010224:Parainfluenza Virus 3, Human / Q000302:isolation & purification; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012129:Respiratory Function Tests; D010253:Respirovirus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D011993:Recombinant Fusion Proteins; C525612:oplunofusp; D010100:Oxygen